Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Cancer Research

• Publication date

  2000-02-15

• Fields of study

  Medicine

• Identifiers
  PMID 10706080
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3.

  1999cited by this paper
• Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors

  1999cited by this paper
• The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts

  1999cited by this paper
• OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

  1999cited by this paper
• Osteoclast markers accumulate on cells developing from human peripheral blood mononuclear precursors

  1999cited by this paper
• A Chimeric Form of Osteoprotegerin Inhibits Hypercalcemia and Bone Resorption Induced by IL‐1β, TNF‐α, PTH, PTHrP, and 1,25(OH)2D3

  1999cited by this paper
• Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function.

  1999cited by this paper
• TRANCE Is Necessary and Sufficient for Osteoblast-mediated Activation of Bone Resorption in Osteoclasts

  1998cited by this paper
• Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

  1998cited by this paper
• Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast.

  1998cited by this paper
• Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

  1998influential reference
• osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.

  1998cited by this paper
• Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

  1997influential reference
• Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis.

  1997cited by this paper
• Anti‐interleukin‐6 receptor antibody prevents muscle atrophy in colon‐26 adenocarcinoma‐bearing mice with modulation of lysosomal and ATP‐ubiquitin‐dependent proteolytic pathways

  1996cited by this paper
• Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo.

  1995cited by this paper
• Hypercalcemia of malignancy: the central role of parathyroid hormone-related protein.

  1994cited by this paper
• Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia.

  1993cited by this paper
• Mechanisms of paraneoplastic syndromes of colon-26: involvement of interleukin 6 in hypercalcemia.

  1993cited by this paper
• Evidence for the involvement of interleukin 6 in experimental cancer cachexia.

  1992cited by this paper
• Humoral hypercalcemia of malignancy.

  1990cited by this paper
• Role of bone and kidney in parathyroid hormone‐related peptide‐induced hypercalcemia in rats

  1989cited by this paper
• Humoral hypercalcemia of malignancy.

  1988cited by this paper
• Parathyroid hormone-related protein purified from a human lung cancer cell line.

  1987cited by this paper
• Parathyroid hormonelike protein from human renal carcinoma cells. Structural and functional homology with parathyroid hormone.

  1987cited by this paper
• Identification of a novel 17,000-dalton parathyroid hormone-like adenylate cyclase-stimulating protein from a tumor associated with humoral hypercalcemia of malignancy.

  1987cited by this paper
• Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: Observations on regulation of serum calcium

  1982cited by this paper
• Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure.

  1975cited by this paper
• Printed in U.S.A. Copyright © 1999 by The Endocrine Society Parathyroid Hormone Stimulates TRANCE and Inhibits Osteoprotegerin Messenger Ribonucleic Acid Expression in Murine Bone Marrow Cultures: Correlation with

  year unknowncited by this paper

• Non-bone metastatic cancers promote osteocyte-induced bone destruction.

  2021cites this paper
• Parathyroid hormone-related peptide and other mediators of skeletal manifestations of malignancy

  2020cites this paper
• Harnessing the versatile role of OPG in bone oncology: counterbalancing RANKL and TRAIL signaling and beyond

  2019cites this paper
• Animal Models of Cancer-Associated Hypercalcemia

  2017cites this paper
• Localization of RANK, RANKL and osteoprotegerin during healing of surgically created periodontal defects in sheep.

  2015cites this paper
• Myeloma and osteoclast relationship

  2015cites this paper
• Advances in Biology and Therapy of Multiple Myeloma

  2013cites this paper
• Breast cancer expression of DAP12 is associated with skeletal and liver metastases and poor survival.

  2013cites this paper
• Novel therapies in benign and malignant bone diseases.

  2012cites this paper
• The role of the bone microenvironment in skeletal metastasis

  2012cites this paper
• Novel Comb-Shaped PEG Modification Enhances the Osteoclastic Inhibitory Effect and Bone Delivery of Osteoprotegerin After Intravenous Administration in Ovariectomized Rats

  2012cites this paper
• Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab

  2012cites this paper
• Molecular Pathways Molecular Pathways : Osteoclast-Dependent and Osteoclast-Independent Roles of the RANKL / RANK / OPG Pathway in Tumorigenesis and Metastasis

  2011cites this paper
• Denosumab for bone diseases: translating bone biology into targeted therapy.

  2011cites this paper
• Establishment of a new murine model of hypercalcemia with anorexia by overexpression of soluble receptor activator of NF-κB ligand using an adenovirus vector

  2011cites this paper
• Osteoclast-dependent and-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis

  2011cites this paper
• OPG/RANKL/RANK pathway as a therapeutic target in cancer.

  2011cites this paper
• Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma

  2010cites this paper
• Targeting RANK/RANKL in the treatment of solid tumours and myeloma.

  2010cites this paper
• Image-Based Hybrid Scaffold Design for Multiple Tissue Regeneration Application in Periodontal Engineering.

  2010influential citation
• Mechanistic Role of RANKL in Cancer-induced Bone Diseases and Development of a Targeted Therapy to Inhibit this Pathway

  2010cites this paper
• Regulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment.

  2010cites this paper
• Therapeutic Potential of Adult Bone Marrow–Derived Mesenchymal Stem Cells in Prostate Cancer Bone Metastasis

  2009cites this paper
• Involvement of molecular mimicry between human T‐cell leukemia virus type 1 gp46 and osteoprotegerin in induction of hypercalcemia

  2009cites this paper
• Therapeutic implications of osteoprotegerin

  2009cites this paper
• DNA methylation and histone modification regulate silencing of OPG during tumor progression

  2009cites this paper
• Pharmacokinetics and disposition of recombinant human osteoprotegerin (rhOPG) after intravenous administration in female fischer rats

  2009influential citation
• Modulation of osteoclast function in bone by the immune system.

  2009cites this paper
• Denosumab: the era of targeted therapies in bone metastatic diseases.

  2009cites this paper
• Systemic and Gene Modified Mesenchymal Stem Cell Therapy for Metastatic Prostate Cancer

  2009cites this paper
• Ciblage thérapeutique des tumeurs osseuses primitives par transfert de gène

  2008cites this paper
• Medical treatment of malignancy-associated hypercalcemia.

  2008cites this paper
• Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis.

  2008cites this paper
• Parathyroid Hormone-Related Peptide and Other Systemic Factors in Skeletal Manifestations of Malignancy

  2008cites this paper
• Therapeutic efficacy of soluble receptor activator of nuclear factor-κB-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma

  2008cites this paper
• TRAIL inhibits osteoclastic differentiation by counteracting RANKL‐dependent p27Kip1 accumulation in pre‐osteoclast precursors

  2008cites this paper
• RANK ligand as a therapeutic target for bone metastases and multiple myeloma.

  2008cites this paper
• Biodistribution and pharmacokinetic studies of bone-targeting N-(2-hydroxypropyl)methacrylamide copolymer-alendronate conjugates.

  2008cites this paper
• Doença óssea em Mieloma Múltiplo Bone disease in Multiple Myeloma

  2007cites this paper
• The RANK/RANKL/OPG triad in cancer-induced bone diseases

  2007cites this paper
• RANKL inhibition through osteoprotegerin blocks bone loss in experimental periodontitis.

  2007cites this paper
• Gene therapy methods in bone and joint disorders

  2007cites this paper
• Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption.

  2007cites this paper
• Parathyroid Hormone-Related Protein Induces Cachectic Syndromes without Directly Modulating the Expression of Hypothalamic Feeding-Regulating Peptides

  2007cites this paper
• Novel host response therapeutic approaches to treat periodontal diseases.

  2007cites this paper
• Osteotropic Peptide that differentiates functional domains of the skeleton.

  2007cites this paper
• Genetically Engineered Animals

  2007cites this paper
• Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis.

  2007cites this paper
• Contrasts with That Delivered Therapeutically Enhances Orthotopic and Osseous Tumor Growth and Osteoprotegerin Overexpression by Breast Cancer Cells

  2006cites this paper
• Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically.

  2006cites this paper
• Laboratory Investigations The Receptor Activator of Nuclear Factor-jB Ligand Inhibitor Osteoprotegerin Is a Bone-Protective Agent in a Rat Model of Chronic Renal Insufficiency and Hyperparathyroidism

  2006cites this paper
• Bedeutung von RANK-Ligand und Osteoprotegerin für den Knochenstoffwechsel

  2006cites this paper
• Role of osteoprotegerin (OPG) in cancer.

  2006cites this paper
• Targeting pathways mediating bone disease.

  2006cites this paper
• Mechanisms of Disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis

  2006cites this paper
• Inhibition of RANKL as a treatment for osteoporosis: Preclinical and early clinical studies

  2006cites this paper
• Mechanisms of Disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis

  2006cites this paper
• OPG/membranous--RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation.

  2006cites this paper
• The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice

  2006cites this paper
• Receptor activator of nuclear ??B ligand and osteoprotegerin: where are we now and what about future treatment uses?

  2005cites this paper
• The Receptor Activator of Nuclear Factor-κB Ligand Inhibitor Osteoprotegerin Is a Bone-Protective Agent in a Rat Model of Chronic Renal Insufficiency and Hyperparathyroidism

  2005cites this paper
• The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy.

  2005cites this paper
• Emerging and potential therapies for osteoporosis

  2005cites this paper
• Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.

  2005cites this paper
• Myeloma bone disease.

  2005cites this paper
• Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.

  2005cites this paper
• TNF-alpha and pathologic bone resorption.

  2005cites this paper
• Exogenous PTH‐Related Protein and PTH Improve Mineral and Skeletal Status in 25‐Hydroxyvitamin D‐1α‐Hydroxylase and PTH Double Knockout Mice

  2005influential citation
• [Hypercalcemia of malignancy: clinical features, diagnosis and treatment].

  2005cites this paper
• Osteoprotegerin Treatment Impairs Remodeling and Apparent Material Properties of Callus Tissue without Influencing Structural Fracture Strength

  2005cites this paper
• Parathyroid hormone–related protein (PTHrP) as a causative factor of cancer‐associated wasting: Possible involvement of PTHrP in the repression of locomotor activity in rats bearing human tumor xenografts

  2005cites this paper
• Effects of anti-parathyroid hormone-related protein monoclonal antibody and osteoprotegerin on PTHrP-producing tumor-induced cachexia in nude mice

  2005cites this paper
• TNFα and pathologic bone resorption

  2005cites this paper
• Bone-targeting macromolecular therapeutics.

  2005cites this paper
• Bisphosphonate treatment does not affect serum levels of osteoprotegerin and RANKL in hypercalcemic cancer patients.

  2005cites this paper
• Designing proteins for bone targeting.

  2005cites this paper
• A hipercalcemia nas malignidades: aspectos clínicos, diagnósticos e terapêuticos

  2005cites this paper
• Textbook of bone metastases

  2005cites this paper
• Potential medical control of periprosthetic bone loss

  2005cites this paper
• The RANKL Inhibitor Osteoprotegerin (OPG) Causes Greater Suppression of Bone Resorption and Hypercalcemia Compared to Bisphosphonates in Two Models of Humoral Hypercalcemia of Malignancy

  2005cites this paper
• Nouvelles approches thérapeutiques des ostéosarcomes.

  2005cites this paper
• A Novel in Vivo Role for Osteoprotegerin Ligand in Activation of Monocyte Effector Function and Inflammatory Response*

  2004cites this paper
• Artyku∏y przeglàdowe • Review articles Post´py w poznaniu patogenezy i leczeniu szpiczaka plazmocytowego

  2004cites this paper
• Revisiting the seed and soil theory of bone metastasis: new tools, same answer.

  2004cites this paper
• Update on the pathogenesis of osteolysis in multiple myeloma patients.

  2004cites this paper
• CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin

  2004cites this paper
• New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).

  2004cites this paper
• The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.

  2004cites this paper
• Novel and Selective Small Molecule Stimulators of Osteoprotegerin Expression Inhibit Bone Resorption

  2004influential citation
• Receptor activator of nuclear factor кB ligand (RANKL) versus osteoprotegerin (OPG): the yin and yang of joint integrity

  2004cites this paper
• OPG, RANK and RANKL in Bone Metastasis and Cancer-Associated Osteolysis

  2004cites this paper
• Opg, RANKl, and RANK in cancer metastasis: expression and regulation.

  2004cites this paper
• RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis.

  2004cites this paper
• Osteoclast Numbers in Lewis Rats with Adjuvant-induced Arthritis: Identification of Preferred Sites and Parameters for Rapid Quantitative Analysis

  2004cites this paper
• Aseptic loosening

  2004cites this paper
• Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice.

  2004cites this paper
• Revisiting the seed and soil theory of bone metastasis: new tools, same answer.

  2004cites this paper
• The Role of Tumor-Associated Macrophages in Metastasis-Associated Osteolysis

  2004cites this paper
• The diagnosis and management of hypercalcaemia.

  2003cites this paper
• A Phase I study of AMGN‐0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases

  2003cites this paper